SHANGHAI (Reuters) – China’s new medical insurance regulator will begin negotiations with domestic and overseas pharmaceutical companies to lower prices of cancer drugs in a bid to cut the financial burden on patients, state news agency Xinhua said on Saturday.
The State Medical Insurance Administration said it was preparing to include more cancer drugs on its list of medicines eligible for reimbursement, and said 10 foreign and eight domestic pharmaceutical companies had expressed a willingness to work with the authority.
Improving insurance coverage is one of the biggest challenges facing China as its population gets older. It has vowed to make medicine and treatment cheaper and more easily available.
China also removed tariffs on all imported cancer drugs starting from May 1, following a decision by Premier Li Keqiang in April.
ULY 14, 2018